Clinical Efficacy Analysis Of Hydromorphone Controlled Subcutaneous Analgesia And Oral Oxycodone Sustained Release Tablets In The Treatment Of Intractable Cancer Pain

Objective: To investigate the differences between hydromorphone subcutaneous controlled analgesia and oral oxycodone in the treatment of refractory cancer pain in terms of analgesic efficacy,adverse reactions,improvement of life quality and medical costs.Methods: 100 patients were collected from Nov.2019-Oct.2020.They were randomly allocated to matched-group and PCSA-group,with 50 cases in each one.The matched-group was treated with oxycodone,and another group was treated with hydromorphone.The analgesic effect,adverse reactions,improvement of life quality and medical expenses between the two groups were observed.Results:1.The pain score of patients in the matched-group 24 hours after administration was(2.89±0.611),compared with the pain score before entering the study(7.44±0.693),and the pain was less severe than before.The pain score of the PCSA group 24 hours after administration was(1.98±1.055),compared with the pain score before the study(7.36±1.026),which was significantly less than before.After the comparison of the pain scores of the two groups,the pain score of the PCSA-group was lower than matchedgroup(P < 0.05).2.After different treatment in the two groups,the adverse reactions of matchedgroup were nausea and vomiting,constipation,pruritus.they were 15 cases,40 case and2cases respectively.There no other adverse reactions occurred.Adverse reactions of PCSA group were nausea and vomiting,constipation,urinary retention,dizziness,they were 6 cases,20 cases,2 cases and 4 cases repectively.Compared with the two groups,the incidence of adverse reactions in PCSA group was lower(P < 0.05).There were no serious adverse reactions in both groups.3.The QOL score of the matched-group before entering the study was(31.62±0.490).After 30 days of treatment,the QOL score was(37.44±2.177).The PCSA group entered the study with a QOL score of(31.4±2.563)and a QOL score of(45.20±2.571)after 30 days of treatment.There was no statistical difference in QOL scores between the two group before joining the study.there was obvious improvment in the quality of life after treatment.The QOL score of PCSA group was higher(P <0.05).4.The average daily morphine dosage of the matched-group was(63.06±9.73),and the average daily morphine dosage of the PCSA group was(55.45±23.43).The average daily expense of the matched-group was(74.32±10.969)yuan,and the average medical expense of the PCSA group was(339.45±144.98)yuan.Conclusions:Oral oxycodone sustained release tablets and hydromorphone controlled subcutaneous analgesia in the treatment of refractory cancer pain,hydromorphone controlled subcutaneous analgesia can better control the pain,with lower incidence of adverse reactions,and could better improve the quality of life of patients.